CRISPR Therapeutics AG
NASDAQ:CRSP
51.88 (USD) • At close November 7, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | CRISPR Therapeutics AG |
Symbool | CRSP |
Munteenheid | USD |
Prijs | 51.88 |
Beurswaarde | 4,428,139,788 |
Dividendpercentage | 0% |
52-weken bereik | 43.42 - 91.1 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Samarth Kulkarni Ph.D. |
Website | https://www.crisprtx.com |
An error occurred while fetching data.
Over CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)